Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing paediatric medicines: identifying the needs and recognizing the challenges.

Terry B Ernest1, David P Elder, Luigi G Martini

  • 1GlaxoSmithKline R&D, Park Road, Ware, Herts SG12 0DP, UK.

The Journal of Pharmacy and Pharmacology
|August 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation into the oral toxicity profile of TruCBN™.

Toxicology reports·2026
Same author

Viscoelastic properties of polymer mixtures containing micro-ribbons and microfibres for the 3D printing of pharmaceutical dosage forms by fused deposition modelling.

The Journal of pharmacy and pharmacology·2026
Same author

Rebuilding HiTOP from the ground up: Symptom-level analyses and a revised mapping to the DSM.

Journal of psychopathology and clinical science·2026
Same author

Study protocol for a feasibility randomised controlled trial of MOVE SMART-An intervention to increase physical activity, reduce sedentary behaviour and improve health outcomes in patients with psoriasis.

PloS one·2026
Same author

The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal.

Addiction biology·2026
Same author

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).

European urology·2026
Same journal

Uterine relaxant effects of Ageratum conyzoides essential oil: influence of hormonal status and calcium modulation.

The Journal of pharmacy and pharmacology·2026
Same journal

Liraglutide-mediated protection against ethanol-induced gastric ulcer in male and female rats: enhancement of mucosal defense, anti-inflammatory and antioxidant mechanism.

The Journal of pharmacy and pharmacology·2026
Same journal

Exploring the mechanism of action of Qufengzhitong pills in treating rheumatoid arthritis via the PI3K/AKT, NF-κB, and MAPK pathways.

The Journal of pharmacy and pharmacology·2026
Same journal

Mechanistic evidence for PI3K/Akt-driven reactivation of Nrf2/HO-1 by dapagliflozin in acute cisplatin hepatotoxicity.

The Journal of pharmacy and pharmacology·2026
Same journal

Advances in nano-drug delivery systems for targeting therapy of breast cancer.

The Journal of pharmacy and pharmacology·2026
Same journal

Zi Shen decoction inhibits non-small cell lung cancer progression by regulating macrophage polarization via the gut microbiota.

The Journal of pharmacy and pharmacology·2026
See all related articles

Developing new medicines for children is crucial, as few are clinically tested, posing risks to this vulnerable group. Challenges include varied development, ethical concerns, and regulatory hurdles.

Area of Science:

  • Pediatric Pharmacology
  • Drug Development
  • Regulatory Science

Background:

  • A significant gap exists in clinically evaluated medicines for pediatric patients.
  • Many marketed drugs lack adequate labeling for pediatric use, increasing patient risk.
  • The unique physiological diversity within the pediatric population complicates drug development.

Purpose of the Study:

  • To review and highlight the challenges in developing medicines for pediatric populations.
  • To underscore the need for increased research and development in pediatric pharmacotherapy.
  • To discuss regulatory and economic factors influencing pediatric drug innovation.

Main Methods:

  • Literature review of existing research on pediatric medicine development.
  • Analysis of regulatory guidelines and incentives from the EU and US.

Related Experiment Videos

  • Examination of ethical considerations in pediatric clinical trials.
  • Discussion of formulation and excipient challenges specific to pediatric use.

    • Main Results:

    • Few drugs are adequately tested or labeled for pediatric use, leading to safety and efficacy concerns.
    • Ethical considerations and the physiological variability of children present significant hurdles in clinical trials.
    • Regulatory bodies acknowledge the need for pediatric medicines, offering incentives to encourage pharmaceutical investment.
    • Excipient suitability and dosage form acceptability pose additional development challenges.

    Conclusions:

    • Addressing the challenges in pediatric medicine development is essential to protect a vulnerable patient group.
    • Regulatory incentives and innovative approaches are needed to overcome development barriers.
    • Further research is vital to ensure safe and effective pharmacotherapy for children.